Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
BCL2-inhibitor venetoclax is used to treat relapsed/refractory chronic lymphocytic leukemia (CLL). Here, the authors show the clonal dynamics towards venetoclax resistance by performing whole-exome sequencing of 8 CLL patients undergoing venetoclax treatment.
Enregistré dans:
Auteurs principaux: | Carmen D. Herling, Nima Abedpour, Jonathan Weiss, Anna Schmitt, Ron Daniel Jachimowicz, Olaf Merkel, Maria Cartolano, Sebastian Oberbeck, Petra Mayer, Valeska Berg, Daniel Thomalla, Nadine Kutsch, Marius Stiefelhagen, Paula Cramer, Clemens-Martin Wendtner, Thorsten Persigehl, Andreas Saleh, Janine Altmüller, Peter Nürnberg, Christian Pallasch, Viktor Achter, Ulrich Lang, Barbara Eichhorst, Roberta Castiglione, Stephan C. Schäfer, Reinhard Büttner, Karl-Anton Kreuzer, Hans Christian Reinhardt, Michael Hallek, Lukas P. Frenzel, Martin Peifer |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/91cad87502c5439c87643a607b72a378 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
par: Schieber M, et autres
Publié: (2019) -
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
par: Richard W. Birkinshaw, et autres
Publié: (2019) -
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
par: Richa Bajpai, et autres
Publié: (2020) -
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia
par: Gero Knittel, et autres
Publié: (2017) -
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance
par: Sylvain Garciaz, et autres
Publié: (2021)